These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34243716)

  • 1. Transmitted drug resistance to Tenofovir/Emtricitabine among persons with newly diagnosed HIV infection in Shenyang city, Northeast China from 2016 to 2018.
    Wang Z; Zhao B; An M; Song W; Dong X; Li X; Wang L; Wang L; Tian W; Ding H; Han X
    BMC Infect Dis; 2021 Jul; 21(1):668. PubMed ID: 34243716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.
    Porter DP; Kulkarni R; Fralich T; Miller MD; White KL
    HIV Clin Trials; 2015; 16(1):30-8. PubMed ID: 25777187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increase of RT-related transmitted drug resistance in non-CRF01_AE among HIV type 1-infected men who have sex with men in the 7 cities of China.
    Zhao B; Han X; Xu J; Hu Q; Chu Z; Zhang J; Lu L; Wang Z; Fu J; Chen X; Yan H; Zhuang M; Wang L; Sun A; Zhang CM; Shang H
    J Acquir Immune Defic Syndr; 2015 Mar; 68(3):250-5. PubMed ID: 25469530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of HIV-1 molecular epidemiology and transmitted drug-resistance in newly diagnosed HIV-infected patients in Sichuan, China.
    Zhou C; Liang S; Li Y; Zhang Y; Li L; Ye L; Yuan D; Su L
    BMC Infect Dis; 2022 Jul; 22(1):602. PubMed ID: 35799101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The S68G polymorphism is a compensatory mutation associated with the drug resistance mutation K65R in CRF01_AE strains.
    Li S; Ouyang J; Zhao B; An M; Wang L; Ding H; Zhang M; Han X
    BMC Infect Dis; 2020 Feb; 20(1):123. PubMed ID: 32046664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128).
    Kulkarni R; Hodder SL; Cao H; Chang S; Miller MD; White KL
    HIV Clin Trials; 2017 Jul; 18(4):164-173. PubMed ID: 28891788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spatial clusters of HIV-1 genotypes in a recently infected population in Yunnan, China.
    Chen M; Ma Y; Chen H; Dai J; Luo H; Yang C; Dong L; Jin X; Yang M; Yang L; Song L; Song Z; Jia M
    BMC Infect Dis; 2019 Jul; 19(1):669. PubMed ID: 31357947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic characterization of HIV-1 epidemic in Anhui Province, China.
    Zhang D; Wu J; Zhang Y; Shen Y; Dai S; Wang X; Xing H; Lin J; Han J; Li J; Qin Y; Liu Y; Miao L; Su B; Li H; Li L
    Virol J; 2020 Feb; 17(1):17. PubMed ID: 32014042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diversity of HIV-1 genotypes and high prevalence of pretreatment drug resistance in newly diagnosed HIV-infected patients in Shanghai, China.
    Wang Z; Zhang M; Zhang R; Liu L; Shen Y; Wang J; Lu H
    BMC Infect Dis; 2019 Apr; 19(1):313. PubMed ID: 30961560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular transmission network analysis reveals the challenge of HIV-1 in ageing patients in China: elderly people play a crucial role in the transmission of subtypes and high pretreatment drug resistance in developed Eastern China, 2019-2023.
    Cao D; Xing H; Feng Y; He T; Zhang J; Ling J; Chen J; Zhao J
    Virol J; 2024 Aug; 21(1):199. PubMed ID: 39187869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic diversity of HIV-1 and transmitted drug resistance among newly diagnosed individuals with HIV infection in Hangzhou, China.
    Zhang J; Guo Z; Yang J; Pan X; Jiang J; Ding X; Zhang W; Xia Y; Xu Y; Huang J
    J Med Virol; 2015 Oct; 87(10):1668-76. PubMed ID: 25899877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural polymorphisms in HIV-1 CRF01_AE strain and profile of acquired drug resistance mutations in a long-term combination treatment cohort in northeastern China.
    Sun Z; Ouyang J; Zhao B; An M; Wang L; Ding H; Han X
    BMC Infect Dis; 2020 Feb; 20(1):178. PubMed ID: 32102660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen.
    Armenia D; Di Carlo D; Calcagno A; Vendemiati G; Forbici F; Bertoli A; Berno G; Carta S; Continenza F; Fedele V; Bellagamba R; Cicalini S; Ammassari A; Libertone R; Zaccarelli M; Ghisetti V; Andreoni M; Ceccherini-Silberstein F; Bonora S; Di Perri G; Antinori A; Perno CF; Santoro MM
    J Antimicrob Chemother; 2017 Mar; 72(3):855-865. PubMed ID: 27999048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic diversity and drug resistance among newly diagnosed and antiretroviral treatment-naive HIV-infected individuals in western Yunnan: a hot area of viral recombination in China.
    Chen M; Ma Y; Duan S; Xing H; Yao S; Su Y; Luo H; Yang L; Chen H; Fu L; Qu A; Ou CY; Jia M; Lu L
    BMC Infect Dis; 2012 Dec; 12():382. PubMed ID: 23270497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study.
    Pedrol E; Caro-Murillo AM; Castaño MA; Riera M; Olalla J; Domingo P; Arazo P; Gómez-Sirvent JL; Pulido F; Romero-Palacios A; Aguirrebengoa K; Vera F; Ferrer P; Blanco Ramos JR
    HIV Clin Trials; 2015; 16(1):43-8. PubMed ID: 25777189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens.
    Svicher V; Alteri C; Artese A; Forbici F; Santoro MM; Schols D; Van Laethem K; Alcaro S; Costa G; Tommasi C; Zaccarelli M; Narciso P; Antinori A; Ceccherini-Silberstein F; Balzarini J; Perno CF
    J Acquir Immune Defic Syndr; 2010 Nov; 55(3):336-44. PubMed ID: 20739898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis.
    Behrens G; Rijnders B; Nelson M; Orkin C; Cohen C; Mills A; Elion RA; Vanveggel S; Stevens M; Rimsky L; Thorpe D; Bosse M; White K; Zhong L; DeMorin J; Chuck SK
    AIDS Patient Care STDS; 2014 Apr; 28(4):168-75. PubMed ID: 24660840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110).
    Porter DP; Kulkarni R; Fralich T; Miller MD; White KL
    J Acquir Immune Defic Syndr; 2014 Mar; 65(3):318-26. PubMed ID: 24525469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients.
    White KL; Kulkarni R; McColl DJ; Rhee MS; Szwarcberg J; Cheng AK; Miller MD
    Antivir Ther; 2015; 20(3):317-27. PubMed ID: 25321623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa.
    Hoffmann CJ; Ledwaba J; Li JF; Johnston V; Hunt G; Fielding KL; Chaisson RE; Churchyard GJ; Grant AD; Johnson JA; Charalambous S; Morris L
    Antivir Ther; 2013; 18(7):915-20. PubMed ID: 23751421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.